Author's response to reviews

Title: Class III beta-tubulin is a predictive marker for taxane-based chemotherapy in recurrent and metastatic gastric cancer

Authors:

Jun-Eul Hwang (hjunyl@naver.com)
Ji-Yun Hong (hongjymd@gmail.com)
Karham Kim (Milktea17@hanmail.net)
Seung-Hun Kim (Sung hun9938@naver.com)
Won-Young Choi (west0917@hanmail.net)
Min-Jee Kim (peekei@hanmail.net)
Sung-Hoon Jung (shglory@hanmail.net)
Hyun-Jeong Shim (hjnhji@hanmail.net)
Woo-Kyun Bae (drwookyun@hanmail.net)
Eu-Chang Hwang (urohwang@gmail.com)
Kyung-Hwa Lee (mdkaylee@jnu.ac.kr)
Jae-Hyuk Lee (jhlee@jnu.ac.kr)
Sang-Hee Cho (shcho@chonnam.ac.kr)
Ik-Joo Chung (ijichung@chonnam.ac.kr)

Version: 2 Date: 26 April 2013

Author's response to reviews: see over
Dear Sir,

Please consider for publication of our manuscript “Class III β-tubulin is a predictive marker for taxane-based chemotherapy in recurrent and metastatic gastric cancer” as a clinical research paper (The subject category: clinical research).

Class III β-tubulin (TUBB3) has been shown to play a role in chemotherapy resistance in various cancer types. However, the role of TUBB3 in gastric cancer has not been widely investigated, although it is important in the treatment of gastric cancer to predict chemosensitivity with the goal of improving the response rate and overall survival (OS), and preventing unnecessary side effects and useless treatments. In this study, we analyzed the significance of TUBB3 and ERCC1 in recurrent and metastatic gastric cancer patients receiving taxane-based first-line palliative chemotherapy.

The manuscript submitted is original, is not under consideration or has not been previously published and its content has not been anticipated by any previous publication. All authors have reviewed the manuscript, agree with its contents, and approve of its submission of “BMC Cancer” for publication consideration.

We would be grateful if the manuscript could be reviewed and considered for publication in BMC Cancer.

Sincerely yours,

Ik-Joo Chung, M.D., Ph.D.
Division of Hematology-oncology, Department of Internal Medicine, Chonnam National University Hwasun Hospital and Medical School, 322 Seoyang-ro, Hwasun-eup, Hwasun-gun, Jeonnam, Gwangju 519-763, Korea. Tel: +82-61-379-7622; Fax: +82-61-379-8019; E-mail: ijchung@chonnam.ac.kr
**Requesting consent statement:**

Please state in the Methods section whether written informed consent for participation in the study was obtained from participants or, where participants are children, a parent or guardian.;

We added following sentence in Methods section.

*Written informed consent was obtained from all patients before study.*